This event has already occurred.
Atique Ahmed, PhD
Neural Stem Cell-Based Virotherapy for Malignant Glioma
Senior Research Associate, Department of Surgery, Section of Neurosurgery, University of Chicago, Chicago, Illinois
2 Riverside Circle, Roanoke, VA 24016
Oncolytic virotherapy for cancer is a novel approach in which viruses are modified to preferentially replicate in the tumor and destroy it. Dr. Ahmed has been interested in the development of novel viral vectors to target human brain tumors. The clinical application of most current viral vector-based anti-cancer therapeutics is limited by the host antiviral immune response and its inability to target disseminated tumor burdens. The discovery of the inherent tumor-tropic properties of stem cells has provided a unique opportunity to develop cell-based targeted therapies. Dr. Ahmed will present his current work in establishing neural stem cells as a cellular delivery vehicle for anti-glioma oncolytic virotherapy. He will also share his experience with conducting FDA-directed preclinical studies in order to secure an Investigational New Drug application for a phase I clinical trial involving patients with invasive glioblastoma.
- Ahmed AU, Thaci B, Alexiades NG, Han Y, Qian S, Liu F, Balyasnikova IV, Ulasov IY, Aboody KS, Lesniak MS. Neural Stem Cell-based Cell Carriers Enhance Therapeutic Efficacy of an Oncolytic Adenovirus in an Orthotopic Mouse Model of Human Glioblastoma. Molecular Therapy, 2011, 19: 1714--26.
- Cole C, Qiao J, Kottke T, Diaz R, Ahmed A, Sanchez-Perez L, Brunn G, Thompson J, Chester J, Vile RG. Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nature Medicine, 2005, 11: 1073--81.
- Ahmed A, Thompson J, Emiliusen L, Murphy S, Beauchamp RD, Suzuki K, Alemany R, Harrington K, Vile RG. A Conditionally Replicating Adenovirus Targeted to Tumor Cells Through Activated RAS/P- MAPK-Selective mRNA Stabilization. Nature Biotech, 2003, 21: 771--77.
About the Speaker:
Atique Ahmed's research focuses on the development of novel oncolytic viruses for anti-cancer therapy; cell based targeted therapies for malignant brain tumors.